Ibogaine Research Database

692 research records indexed from PubMed. Plain-language summaries where available.

Of these, 52 are human clinical studies (trials, observational studies, or case reports), 398 are preclinical (animal or lab) studies, and 112 are reviews or meta-analyses summarizing other researchers’ data. A record appearing here does not by itself mean ibogaine is proven effective for a given condition — see each condition page’s evidence breakdown for what’s actually established.

Compare evidence by condition →

All Studies (692)Depression (56)PTSD (24)Alcohol Addiction (20)Heroin Addiction (16)Opioid Addiction (15)Cocaine Addiction (15)Anxiety (13)Methamphetamine Addiction (12)Traumatic Brain Injury (2)

All Studies(692 of 692)

Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine.

Henstra, Wong, Chahbouni et al.· Clin Toxicol (Phila)· 2017· PMID: 28489458
Case Report

Ibogaine is an agent that has been evaluated as an unapproved anti-addictive agent for the management of drug dependence. Sudden cardiac death has been described to occur secondary to its use. We describe the clinical effects and toxicokinetics of ibogaine and noribogaine in a si...

Anxiolytic-like effects of noribogaine in zebrafish.

Kalueff, Kaluyeva, Maillet· Behav Brain Res· 2017· PMID: 28479267
Preclinical (Animal)

Noribogaine is the main psychoactive metabolite of the hallucinogenic drug ibogaine, and is a particularly interesting compound potentially useful to treat dependence and various psychiatric disorders. Here, we report the effects of noribogaine on anxiety and locomotion in zebraf...

Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences.

Heink, Katsikas, Lange-Altman· J Psychoactive Drugs· 2017· PMID: 28266890
Unclassified

Psychedelic drugs have historically been used for ritualistic purposes and to help individuals gain insight. Ibogaine, a naturally occurring psychoactive substance, has been reported to have anti-addictive properties that aid in the treatment of substance use disorders. An online...

Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning.

Davis, Barsuglia, Windham-Herman et al.· J Psychedelic Stud· 2017· PMID: 30272050
Preclinical (Lab)

Very few studies have reported the effectiveness of ibogaine as a treatment for chronic opioid use. Therefore, this study evaluated the acute subjective effects of ibogaine, outcomes on problematic opioid consumption, and the long-term associations with psychological functioning....

Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Rubi, Eckert, Boehm et al.· Cardiovasc Toxicol· 2017· PMID: 27020671
Preclinical (Lab)

Ibogaine is a plant alkaloid used as anti-addiction drug in dozens of alternative medicine clinics worldwide. Recently, alarming reports of life-threatening cardiac arrhythmias and cases of sudden death associated with the ingestion of ibogaine have accumulated. Using whole-cell ...

Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound.

Gassaway, Jacques, Kruegel et al.· ACS Chem Biol· 2016· PMID: 26517751
Preclinical (Animal)

Modulation of growth factor signaling pathways in the brain represents a new experimental approach to treating neuropsychiatric disorders such as depression, anxiety, and addiction. Neurotrophins and growth factors exert synaptic, neuronal, and circuit level effects on a wide tem...

When transporters fail to be transported: how to rescue folding-deficient SLC6 transporters.

Sucic, Kasture, Mazhar Asjad et al.· J Neurol Neuromedicine· 2016· PMID: 28405636
Preclinical (Lab)

The human dopamine transporter (hDAT) belongs to the solute carrier 6 (SLC6) gene family. Point mutations in hDAT (SLC6A3) have been linked to a syndrome of dopamine transporter deficiency or infantile dystonia/parkinsonism. The mutations impair DAT folding, causing retention of ...

In reply - on the toxicity of ibogaine.

Brunt, Litjens· Clin Toxicol (Phila)· 2016· PMID: 27243280
Preclinical (Lab)

18-Methoxycoronaridine acts in the medial habenula to attenuate behavioral and neurochemical sensitization to nicotine.

Eggan, McCallum· Behav Brain Res· 2016· PMID: 27059333
Preclinical (Animal)

Systemic 18-methoxycoronaridine, an alpha3beta4 nicotinic antagonist, slows the rate of induction of behavioral sensitization to nicotine (Glick et al., 1996; 2011). The primary mechanism of action of 18-MC is believed to be the inhibition of α3β4 nicotinic acetylcholine receptor...

The Journal of biological chemistry

Kasture, El-Kasaby, Szöllősi et al.· J Biol Chem· 2016· PMID: 27481941
Preclinical (Animal)

Folding-defective mutants of the human dopamine transporter (DAT) cause a syndrome of infantile dystonia/parkinsonism. Here, we provide a proof-of-principle that the folding deficit is amenable to correction in vivo by two means, the cognate DAT ligand noribogaine and the HSP70 i...

Ibogan, Aspidosperman, Vincamine, and Bisindole Alkaloids from a Malayan Tabernaemontana corymbosa: Iboga Alkaloids with C-20α Substitution.

Nge, Chong, Thomas et al.· J Nat Prod· 2016· PMID: 27077800
Unclassified

Ten new indole alkaloids (1-10) comprising five ibogan, two aspidosperman, one vincamine, and two bisindole alkaloids, in addition to 32 known alkaloids, were isolated from the stem-bark extract of a Malayan Tabernaemontana corymbosa. The structures of these alkaloids were determ...

Death related to consumption of Rauvolfia sp. powder mislabeled as Tabernanthe iboga.

Gicquel, Hugbart, Le Devehat et al.· Forensic Sci Int· 2016· PMID: 27342343
Case Report

Powdered roots of iboga (Tabernanthe iboga) contain ibogaine, an alkaloid that has been used to treat addictions. We report the case of a 30-year-old woman who died after ingesting a powder labeled as Tabernanthe iboga she had bought online. Analysis of the powder revealed the ab...

Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells.

Beerepoot, Lam, Salahpour· J Biol Chem· 2016· PMID: 27555326
Unclassified

A number of pathological conditions have been linked to mutations in the dopamine transporter gene, including hereditary dopamine transporter deficiency syndrome (DTDS). DTDS is a rare condition that is caused by autosomal recessive loss-of-function mutations in the dopamine tran...

Vobasinyl-Iboga Alkaloids from Tabernaemontana elegans: Cell Cycle Arrest and Apoptosis-Inducing Activity in HCT116 Colon Cancer Cells.

Paterna, Gomes, Borralho et al.· J Nat Prod· 2016· PMID: 27704811
Unclassified

Phytochemical investigation of the roots of the African medicinal plant Tabernaemontana elegans led to the isolation of three new (1-3) and two known (4 and 5) bisindole alkaloids of the vobasinyl-iboga type. The structures of 1-3 were assigned by spectroscopic methods, mainly us...

Pharmacokinetics of hERG Channel Blocking Voacangine in Wistar Rats Applying a Validated LC-ESI-MS/MS Method.

Mair, de Miranda Silva, Grienke et al.· Planta Med· 2016· PMID: 27257769
Preclinical (Animal)

Herbal preparations from Voacanga africana are used in West and Central African folk medicine and are also becoming increasingly popular as a legal high in Europe. Recently, the main alkaloid voacangine was found to be a potent human ether-à-go-go-related gene channel blocker in ...

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.

Mash, Ameer, Prou et al.· J Psychopharmacol· 2016· PMID: 27044509
Preclinical (Animal)

This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administratio...

Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.

Glue, Cape, Tunnicliff et al.· Clin Pharmacol Drug Dev· 2016· PMID: 27870477
Randomized Controlled Trial

Ibogaine is a psychoactive substance that may reduce opioid withdrawal symptoms. This was the first clinical trial of noribogaine, ibogaine's active metabolite, in patients established on methadone opioid substitution therapy (OST). In this randomized, double-blind, placebo-contr...

Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics.

Glue, Cape, Tunnicliff et al.· J Clin Pharmacol· 2016· PMID: 26763764
Clinical Trial

The aim of this study was to switch patients established on methadone opioid substitution therapy (OST) to morphine over 1 week. Subjects established on daily methadone OST (mean dose 60 mg/day) were switched to morphine slow-release capsules, dosed at 4× the previous total daily...

Cytotoxic monoterpenoid indole alkaloids isolated from the barks of Voacanga africana Staph.

Chen, Yang, Li et al.· Nat Prod Res· 2016· PMID: 26140390
Unclassified

A new monoterpenoid indole alkaloid compound (1) and six known monoterpenoid indole alkaloids compounds (2-7) were isolated from the barks of Voacanga africana Staph. The structures were established by spectral analysis as ibogamine-16-carboxylic acid,17,20-didehydro-5,6-dioxo-10...

Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys.

Authier, Accardi, Paquette et al.· J Pharmacol Toxicol Methods· 2016· PMID: 27126304
Preclinical (Animal)

Continuous video-electroencephalographic (EEG) monitoring remains the gold standard for seizure liability assessments in preclinical drug safety assessments. EEG monitored by telemetry was used to assess the behavioral and EEG effects of noribogaine hydrochloride (noribogaine) in...

Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats.

Rezvani, Cauley, Slade et al.· Pharmacol Biochem Behav· 2016· PMID: 27984095
Preclinical (Animal)

The ibogaine derivative 18-methoxycoronaridine (18-MC) has been found to decrease self-administration of morphine, nicotine and alcohol in rats after systemic injection. However oral dosing is the preferred route clinically. The current study evaluated the effect of oral 18-MC do...

A Case of QT Prolongation and Torsades de Pointes Caused by Ibogaine Toxicity.

Hildyard, Macklin, Prendergast et al.· J Emerg Med· 2016· PMID: 26329675
Case Report

Get Clean or Die Trying.

Nestor· Scientific American· 2016· PMID: 27918503
Unclassified

Control of serotonin transporter phosphorylation by conformational state.

Zhang, Turk, Rudnick· Proc Natl Acad Sci U S A· 2016· PMID: 27140629
Unclassified

Serotonin transporter (SERT) is responsible for reuptake and recycling of 5-hydroxytryptamine (5-HT; serotonin) after its exocytotic release during neurotransmission. Mutations in human SERT are associated with psychiatric disorders and autism. Some of these mutations affect the ...

Quantification of Anti-Addictive Alkaloids Ibogaine and Voacangine in In Vivo- and In Vitro-Grown Plants of Two Mexican Tabernaemontana Species.

Krengel, Herrera Santoyo, Olivera Flores et al.· Chem Biodivers· 2016· PMID: 27448833
Preclinical (Lab)

Tabernaemontana alba and Tabernaemontana arborea are Apocynaceae species used in Mexican traditional medicine for which little phytochemical information exists. In this study, preliminary gas chromatography/mass spectrometry analyses of different organs obtained from wild plants ...

Bioinspired Collective Syntheses of Iboga-Type Indole Alkaloids.

Zhao, Xie, Sun et al.· Org Lett· 2016· PMID: 27160167
Preclinical (Lab)

We present the application of a bioinspired collective synthesis strategy in the total syntheses of seven iboga-type indole alkaloids: (±)-tabertinggine, (±)-ibogamine, (±)-ibogaine, (±)-ibogaine hydroxyindolenine, (±)-3-oxoibogaine hydroxyindolenine, (±)-iboluteine, and (±)-erva...

hERG Blockade by Iboga Alkaloids.

Alper, Bai, Liu et al.· Cardiovasc Toxicol· 2016· PMID: 25636206
Unclassified

The iboga alkaloids are a class of naturally occurring and synthetic compounds, some of which modify drug self-administration and withdrawal in humans and preclinical models. Ibogaine, the prototypic iboga alkaloid that is utilized clinically to treat addictions, has been associa...

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Cloutier-Gill, Wood, Millar et al.· J Psychoactive Drugs· 2016· PMID: 27192438
Case Report

Opioid use disorders (OUD) translate into major health, social, and economic consequences. Opioid agonist medications, which generally require long-term administration, are the mainstay pharmacological treatment of OUD. However, a large proportion of individuals with OUD either r...

Effects of low dose ibogaine on subjective mood state and psychological performance.

Forsyth, Machado, Jowett et al.· J Ethnopharmacol· 2016· PMID: 27180314
Randomized Controlled Trial

Root bark from Tabernanthe iboga has been used traditionally in West Africa as a psychoactive substance in religious rituals. In smaller doses it is reported anecdotally to have stimulant properties. To evaluate the influence of a single 20mg ibogaine dose on psychological variab...

On the toxicity of ibogaine.

Yip, Deng· Clin Toxicol (Phila)· 2016· PMID: 27243473
Preclinical (Lab)

[Ibogaine - structure, influence on human body, clinical relevance].

Zdrojewicz, Kuszczak, Olszak· Pol Merkur Lekarski· 2016· PMID: 27734823
Review

Ibogaine is a natural chemical compound, which belongs to the indole alkaloid family. It can be naturally found within the root bark of african plant Tabernanthe iboga. Ibogaine plays a significant role among tribal cultures. Ibogaine, in small amount, causes reduction of hunger,...

Ibogaine for treating drug dependence. What is a safe dose?

Schep, Slaughter, Galea et al.· Drug Alcohol Depend· 2016· PMID: 27426011
Review

The indole alkaloid ibogaine, present in the root bark of the West African rain forest shrub Tabernanthe iboga, has been adopted in the West as a treatment for drug dependence. Treatment of patients requires large doses of the alkaloid to cause hallucinations, an alleged integral...

Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Belgers, Leenaars, Homberg et al.· Transl Psychiatry· 2016· PMID: 27244235
Meta-Analysis

Ibogaine is a naturally occurring substance which has been increasingly used in the lay-scene to reduce craving and relapse in patients with substance use disorders (SUDs). Although human clinical trials on the safety and efficacy of ibogaine are lacking, animal studies do suppor...

Ibogaine-associated cardiac arrest and death: case report and review of the literature.

Meisner, Wilcox, Richards· Ther Adv Psychopharmacol· 2016· PMID: 27141291
Review

A naturally occurring hallucinogenic plant alkaloid, ibogaine has been used as an adjuvant for opiate withdrawal for the past 50 years. In the setting of an escalating nationwide opiate epidemic, use of substances such as ibogaine may also increase. Therefore, familiarity with th...

How toxic is ibogaine?

Litjens, Brunt· Clinical toxicology (Philadelphia, Pa.)· 2016· PMID: 26807959
Review

Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga. It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. To review ibogaine's pharmacokinetics and p...

Screening approach by ultra-high performance liquid chromatography-tandem mass spectrometry for the blood quantification of thirty-four toxic principles of plant origin. Application to foren

Carlier, Guitton, Romeuf et al.· J Chromatogr B Analyt Technol Biomed Life Sci· 2015· PMID: 25438245
Unclassified

Plant poisonings have left their mark on history and still cause many deaths, whether intentional or accidental. The means to show toxicological evidence of such poisonings should be implemented with great care. This article presents a technique for measuring thirty-nine toxic pr...

Can psychedelic compounds play a part in drug dependence therapy?

Sessa, Johnson· Br J Psychiatry· 2015· PMID: 25561484
Unclassified

After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but t...

High-performance thin-layer chromatography for the evaluation of voacamine intracellular concentration related to its cytotoxic effect.

Condello, Multari, Gallo et al.· J Pharm Biomed Anal· 2015· PMID: 26298394
Unclassified

Previous investigations demonstrated that pretreatment with non-cytotoxic concentrations of voacamine had a chemosensitizing effect on cultured multidrug resistant osteosarcoma cells exposed to doxorubicin; whereas when used alone at high concentrations voacamine induced apoptosi...

Coronaridine, an iboga type alkaloid from Tabernaemontana divaricata, inhibits the Wnt signaling pathway by decreasing β-catenin mRNA expression.

Ohishi, Toume, Arai et al.· Bioorg Med Chem Lett· 2015· PMID: 26231157
Unclassified

Four alkaloids, voacangine (1), isovoacangine (2), coronaridine (3), and coronaridine hydroxyindolenine (4), were isolated from the MeOH extract of Tabernaemontana divaricata aerial parts by activity-guided fractionation for Wnt signal inhibitory activity. Compounds 1-4 exhibited...

Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.

Arias, Targowska-Duda, Feuerbach et al.· Int J Biochem Cell Biol· 2015· PMID: 26022277
Unclassified

To characterize the interaction of coronaridine congeners with human (h) α3β4 nicotinic acetylcholine receptors (AChRs), structural and functional approaches were used. The Ca(2+) influx results established that coronaridine congeners noncompetitively inhibit hα3β4 AChRs with the...

Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability.

Glue, Lockhart, Lam et al.· J Clin Pharmacol· 2015· PMID: 25279818
Randomized Controlled Trial

Noribogaine is the active metabolite of the naturally occurring psychoactive substance ibogaine, and may help suppress withdrawal symptoms in opioid-dependent subjects. The objectives of this Phase I study were to assess the safety, tolerability, pharmacokinetic, and pharmacodyna...

Noribogaine is a G-protein biased κ-opioid receptor agonist.

Maillet, Milon, Heghinian et al.· Neuropharmacology· 2015· PMID: 26302653
Preclinical (Animal)

Noribogaine is the long-lived human metabolite of the anti-addictive substance ibogaine. Noribogaine efficaciously reaches the brain with concentrations up to 20 μM after acute therapeutic dose of 40 mg/kg ibogaine in animals. Noribogaine displays atypical opioid-like components ...

Pharmacotherapy: Quest for the quitting pill.

Willyard· Nature· 2015· PMID: 26107096
Preclinical (Animal)

Noribogaine reduces nicotine self-administration in rats.

Chang, Hanania, Mash et al.· J Psychopharmacol· 2015· PMID: 25995321
Preclinical (Animal)

Noribogaine, a polypharmacological drug with activities at opioid receptors, ionotropic nicotinic receptors, and serotonin reuptake transporters, has been investigated for treatment of substance abuse-related disorders. Smoking cessation has major benefits for both individuals an...

Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels.

O'Connell, Gerona, Friesen et al.· Am J Emerg Med· 2015· PMID: 25687617
Case Report

Ibogaine, a psychotropic indole alkaloid, is gaining popularity among medical subcultures for its purported anti addictive properties. Its use has been associated with altered mental status, ataxia, gastrointestinal distress, ventricular arrhythmias, and sudden and unexplained de...

"Herbal seizures"--atypical symptoms after ibogaine intoxication: a case report.

Breuer, Kasper, Schwarze et al.· J Med Case Rep· 2015· PMID: 26518760
Case Report

Misuse of various new psychotropic substances such as ibogaine is increasing rapidly. Knowledge of their negative side effects is sparse. We present a case of intoxication with the herbal substance ibogaine in a 22-year-old white man. After taking a cumulative dose of 38 g (taken...

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.

Glue, Winter, Garbe et al.· J Clin Pharmacol· 2015· PMID: 25651476
Clinical Trial

Conversion of ibogaine to its active metabolite noribogaine appears to be mediated primarily by CYP2D6. We compared 168 hours pharmacokinetic profiles of both analytes after a single oral 20 mg dose of ibogaine in 21 healthy subjects who had been pretreated for 6 days with placeb...

Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes.

Nikolić-Kokić, Oreščanin-Dušić, Spasojević et al.· J Ethnopharmacol· 2015· PMID: 25660330
Preclinical (Lab)

Ibogaine is a naturally occurring alkaloid with psychotropic and metabotropic effects, derived from the bark of the root of the West African Tabernanthe iboga plant. The tribes of Kongo basin have been using iboga as a stimulant, for medicinal purposes, and in rite of passage cer...

[Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca].

Szabó, Kazai, Frecska et al.· Neuropsychopharmacol Hung· 2015· PMID: 26485742
Review

In lack of professional research and appropriate concepts our scientific knowledge of psychedelic agents is limited. According to the long-held official view these drugs are entirely harmful and have no medical use. However, a recent surge of clinical and pharmacological studies ...

Mania following use of ibogaine: A case series.

Marta, Ryan, Kopelowicz et al.· Am J Addict· 2015· PMID: 25877487
Case Series

Ibogaine is a naturally occurring hallucinogen with postulated anti-addictive qualities. While illegal domestically, a growing number of individuals have sought it out for treatment of opiate dependence, primarily in poorly regulated overseas clinics. Existing serious adverse eve...

← PrevPage 6 / 14Next →